The second is the combination of cutaneous toxicity (rash, paronychia) and venous thromboembolism (VTE), which requires ...
Dr. Rodriguez discusses CNS surveillance for Mr. Smith, who has selected subcutaneous (SC) amivantamab plus lazertinib for ...
Dr. Rodriguez walks through the central nervous system (CNS) efficacy data for the three first-line options. She notes that ...
Dr. Rodriguez describes the current period in EGFR-positive lung cancer as one of active change in the first-line landscape: ...
In closing, Dr. Rodriguez emphasizes that for patients who present with brain metastases, first-line treatment selection in ...
Fast track status supports expedited development/review for a serious hematologic malignancy with limited second-line therapy after HMA failure. CyTAC engineering merges small-molecule CCR2 binding ...
FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.
The FDA's recent authorization of an expanded access program (EAP) for daraxonrasib (RMC-6236) has sparked widespread ...
In an interview with Targeted Oncology, Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center, ...
Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, ...
Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...
NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results